Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Apple

Surgery Austin, TX Medical Doctor

NPI 1750354924 CMS profile 34276

1010 W 40Th St, Austin, TX 78756

Open in the dashboard

General payments

$48,517

259 records reported · program years 2019–2025

Research payments

$255

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$170,179 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jeffrey Apple of Austin, TX is reported in the CMS Open Payments database as having received $48,517 across 259 general payments and $255 in research payments paid to them. Separately, studies naming them as principal investigator received $170,179 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,256 47
2024 General $9,783 94
2023 General $15,476 47
2022 General $15,748 36
2021 General $3,498 20
2020 General $363 10
2020 Research $255 1
2019 General $394 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Apple
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Jeffrey Apple were reported at $3,256. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Jeffrey Apple Surgery median Middle half National median
2019 $394 $253 $82–$1,521 $163
2020 $363 $131 $40–$706 $114
2021 $3,498 $168 $50–$904 $132
2022 $15,748 $224 $76–$1,218 $149
2023 $15,476 $253 $82–$1,255 $160
2024 $9,783 $279 $90–$1,381 $164
2025 $3,256 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Cook Incorporated $25,768 14 payments
  2. Silk Road Medical, Inc. $8,041 32 payments
  3. Medtronic, Inc. $5,176 37 payments
  4. Cook Medical LLC $4,962 88 payments
  5. Penumbra, Inc. $936 17 payments
  6. W. L. Gore & Associates, Inc. $883 12 payments
  7. Boston Scientific Corporation $262 9 payments
  8. CVRx, Inc. $257 5 payments
  9. Atricure, Inc. $207 2 payments
  10. Terumo Medical Corporation $191 3 payments
  11. Other $1,834 40 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $24,500 7 payments
  2. Food and Beverage $9,589 216 payments
  3. Travel and Lodging $7,278 32 payments
  4. Consulting Fee $7,150 4 payments
Products named General payments · program years 2019–2025
  1. Zilver Vena Peripheral Intervention $19,816 24 payments
  2. ENROUTE Transcarotid Stent $7,995 30 payments
  3. ENROUTE Transcarotid Neuroprotection System $7,995 30 payments
  4. Cook Celect $4,621 3 payments
  5. ZILVER VENA Peripheral Intervention $4,144 8 payments
  6. ENDURANT IIS $3,311 23 payments
  7. ENHANCE Transcarotid Peripheral Access Kit $3,109 9 payments
  8. ENROUTE .014 Guidewire $3,109 9 payments
  9. Zilver PTX $1,146 20 payments
  10. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $755 11 payments
  11. Other $7,015 156 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Cook Research Incorporated $255 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

304

Median for Vascular Surgery: 122

Drug cost

$116,929

Median for Vascular Surgery: $14,135

Branded share of claims

100%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 112 $70,494
Xarelto Rivaroxaban Brand 54 $44,961
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 69 $768
Clopidogrel Clopidogrel Bisulfate Brand 69 $705

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 141 billing codes

Paid by Medicare

$337,304

Medicare's payments for the services billed

Medicare patients

572

Average age 74

Services billed

1,564

275 women, 297 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Ischemic heart disease 43%
Diabetes 36%
Chronic kidney disease 32%
Atrial fibrillation 25%
Depression 24%
Heart failure 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

260 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record